Want to see GB:ABDX full AI Analyst Report?
ABDX Stock Chart & Stats
9.75 p
0.10 p(1.03%)
At close: 4:00 PM EDT
9.75 p
0.10 p(1.03%)
Day’s Range― - ―
52-Week Range5.10 p - 13.00 p
Previous CloseN/A
Volume87.84K
Average Volume (3M)78.74K
Market Cap
£26.54M
Enterprise Value22.52 p
Total Cash (Recent Filing)£3.71M
Total Debt (Recent Filing)£948.00K
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Nov 18, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,751,500
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£15.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth of ~23.6% indicates expanding commercial traction in rapid diagnostics and growing demand for its services. Over a 2-6 month horizon this supports backlog visibility, scale benefits in manufacturing and strengthens commercial positioning versus peers.
B2B Contract Manufacturing ModelA B2B service-and-manufacturing model yields recurring, volume-linked revenue from third parties. Durable contracts and end-to-end development-to-manufacture offerings create predictable cash flows and customer stickiness as partners outsource rapid-test production.
Manageable LeverageLow relative debt provides financial flexibility to invest in capacity, R&D and absorb near-term operating losses. Manageable leverage reduces refinancing risk and preserves optionality for strategic partnerships or capital raises over the medium term.
Bears Say
Negative ProfitabilityPersistent negative net profit and EBIT margins show the business is not converting sales into sustainable earnings. Without margin recovery, retained earnings remain constrained, limiting self-funding for growth and increasing reliance on external capital over months.
Declining Gross MarginA falling gross margin signals cost pressures or pricing weakness at the core product level. If structural, this erodes operating leverage and caps the ability to reach breakeven even as revenue rises, making profitability improvements harder to achieve.
Negative Operating Cash FlowOperating activities do not generate cash, increasing dependence on financing or equity raises to fund working capital and capex. This structural cash shortfall can constrain investments, slow product development, and raise liquidity risk in coming quarters.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.10 p and its highest was 13.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £26.54M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Nov 18, 2026 which is in 96 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Mar 17, 2026. The company reported -0.004 p earnings per share for the quarter, beating the consensus estimate of -0.006 p by 0.002 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate is <0.01.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 252,751,500 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of -0.004 p in its last earnings report, beating expectations of -0.006 p. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―